Hanbang Technology IPO Filed with Shanghai Stock Exchange, Focusing on Chromatographic Separation and Purification Products

On February 24, Jiangsu Hanbang Technology Co., Ltd. (hereinafter referred to as "Hanbang Technology") applied for IPO review status change to "submitted for registration" on the Shanghai Stock Exchange's Science and Technology Innovation Board (hereinafter referred to as "the Science and Technology Innovation Board"). China Citic Securities is its sponsor and it plans to raise RMB598 million. The prospectus reveals that Hanbang Technology is a high-tech enterprise integrating R&D, production and sales, with chromatography technology as its core, dedicated to "purifying chromatography technology for human health" and striving to "establish the first brand in the international chromatography industry". It mainly provides professional separation and purification equipment, consumables, application services and related technical solutions for pharmaceuticals, life sciences and other fields. Through continuous R&D, Hanbang Technology has broken through the technical difficulties in chromatography linear amplification and achieved linear amplification of separation and purification from gram-level, ten gram-level, hundred gram-level to kilogram-level. Its products and technologies are widely applied in the R&D and production of antibodies, recombinant proteins, vaccines, insulin, peptides, contrast agents, antibiotics and other drugs and natural products, breaking the long-term monopoly of foreign related technologies and products and becoming a leading enterprise in the R&D, production and industrialization of chromatography separation and purification equipment in China, effectively promoting the domestic substitution of chromatography separation and purification equipment and upgrading the industry of downstream pharmaceuticals. The Company's main products can be divided into small molecule drug separation and purification equipment and large molecule drug separation and purification equipment according to types, which can be widely applied in various application scenarios in industrial production and laboratory R&D. During the reporting period, the Company responded to the downstream market demand for various equipment products in a timely manner and actively developed overseas markets with its comprehensive product layout and leading customer service capabilities. The Company's main business revenue has grown at a compound annual growth rate of 38.99% from 2021 to 2023. The Company will invest in the following projects after deducting the corresponding issuance fees from the proceeds of this public offering: Financially, Hanbang Technology achieved revenue of approximately RMB321 million, RMB482 million, RMB619 million and RMB329 million in 2021, 2022, 2023 and 1-6 months of 2024, respectively. During the same period, the Company achieved net profit of approximately RMB4.86 million, RMB38.56 million, RMB51.49 million and RMB37.68 million, respectively.